Reiteration https://www.benzinga.com/views/taxonomy/term/39823 en Canopy Growth Is Growing More Pot Than It Can Sell, MKM Says https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16181341/canopy-growth-is-growing-more-pot-than-it-can-sell-mkm-says <p>While <strong>Canopy Growth Corp</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>) has announced strategic changes that could help lower its cost burden, the company is &ldquo;sized for growth&rdquo; that may not materialize in the medium-term, according to MKM Partners.</p> <h3>The Canopy Growth Analyst</h3> <p><a href="https://www.tipranks.com/analysts/william-kirk">Bill Kirk</a> maintained a Neutral rating on Canopy Growth and reduced the price target from CA$21 ($15.56) to CA$19 ($14.08).</p> <h3>The Canopy Growth Thesis</h3> <p>Canopy Growth reported sequential deceleration in revenue and a wider EBITDA loss for the fiscal fourth quarter, while most peers announced sequential improvements, Kirk said in a Thursday note. (See ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16181341/canopy-growth-is-growing-more-pot-than-it-can-sell-mkm-says alt=Canopy Growth Is Growing More Pot Than It Can Sell, MKM Says>Full story available on Benzinga.com</a></p> Analyst Color Bill Kirk Cannabis CGC MKM Partners Price Target Reiteration Markets Analyst Ratings CGC Analyst Color Cannabis Price Target Reiteration Markets Analyst Ratings Benzinga Thu, 04 Jun 2020 18:42:10 +0000 Priya Nigam 16181341 at https://www.benzinga.com Cloudera Analysts Say Private, Public Cloud Traction Key After Mixed Q1 https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16180687/cloudera-analysts-say-private-public-cloud-traction-key-after-mixed-q1 <p>Cloud-based enterprise data company <strong>Cloudera Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cldr#NYSE">CLDR</a>) reported better-than-expected first-quarter results but issued below-par guidance Wednesday, sending its <a href=" https://www.benzinga.com/news/20/06/16178062/33-stocks-moving-in-thursdays-pre-market-session"> shares </a> lower.</p> <h3>The Cloudera Analysts</h3> <p>BofA Securities analyst <a href="https://www.tipranks.com/analysts/kash-rangan"> Kash Rangan </a> reiterated an Underperform rating on <a href="https://www.benzinga.com/media/19/12/14949333/ea-cloudera-and-more-fast-money-halftime-report-picks-from-dec-6">Cloudera shares</a>&nbsp;with an $8 price target.</p> <p>Wedbush analyst <a href="https://www.tipranks.com/analysts/daniel-ives"> Daniel Ives </a> maintained a Neutral rating and hiked the price target from $12 to $14.</p> <p>Needham analyst <a href="https://www.tipranks.com/analysts/jack-andrews"> Jack Andrews </a> reiterated a Hold rating.</p> <p>Stifel analyst <a href="https://www.tipranks.com/analysts/brad-reback"> Brad Reback </a> maintained a Hold rating and $11 price target.</p> <p>Morgan Stanley analyst <a href="https://www.tipranks.com/analysts/sanjit-singh"> Sanjit Singh</a> maintained an Overweight rating and nudged up the price target from $14 to $15.</p> <h3>Cloudera&#39;s Long-Term Guidance Could Be Challenging, BofA Says</h3> <p>Cloudera&#39;s first-quarter results reflected a large deal size momentum, lower churn, higher renewal rates and adoption of new products, Rangan said in a Thursday note.</p> <p>The company may find it challenging to achieve its longer-term guidance of 15-20%-plus&nbsp;revenue growth and 20%-plus cash flow margins due to several moving pieces, the analyst said.&nbsp;</p> <p>Among the challenges Rangan highlighted were sustained intense competition from public cloud vendors, uncertainty over the success of its recently released first-generation CDP Public Cloud and the likelihood of the yet-to-be released CDP Private Cloud succeeding.&nbsp;</p> <p>BofA attributed the lowered price target to&nbsp;lower revenue ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16180687/cloudera-analysts-say-private-public-cloud-traction-key-after-mixed-q1 alt=Cloudera Analysts Say Private, Public Cloud Traction Key After Mixed Q1>Full story available on Benzinga.com</a></p> Analyst Color BofA Securities Brad Reback CLDR cloud Daniel Ives Earnings Jack Andrews Kash Rangan Morgan Stanley Needham News Sanjit Singh Stifel Wedbush Guidance Price Target Reiteration Analyst Ratings Tech Trading Ideas CLDR US1890971088 News Analyst Color Earnings Guidance Price Target Reiteration Analyst Ratings Tech Trading Ideas Benzinga Thu, 04 Jun 2020 18:27:15 +0000 Shanthi Rexaline 16180687 at https://www.benzinga.com 4 Reasons Why This Monster Beverage Analyst Raised Their Price Target https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16180646/4-reasons-why-this-monster-beverage-analyst-raised-their-price-target <p>Energy beverage maker <strong>Monster Beverage Corp</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mnst#NASDAQ">MNST</a>) hosted a&nbsp;<a href="https://www.benzinga.com/pressreleases/20/05/g16110616/monster-beverage-announces-webcast-details-for-annual-meeting-of-stockholders">virtual annual general meeting</a>&nbsp;this week that signaled the company is &quot;going full beast mode,&quot; according to BofA Securities.&nbsp;</p> <h3>The Monster Beverage Analyst</h3> <p><a href="https://www.tipranks.com/analysts/peter-galbo">Peter Galbo</a> maintained&nbsp;a Buy rating on Monster Beverage&#39;s stock with a price target lifted from $70 to $80.</p> <h3>The Monster Beverage Thesis</h3> <p>Monster Beverage&#39;s virtual meeting supported an incrementally bullish stance on the stock for four reasons, Galbo said in a Thursday note. (See his track record <a href="http://www.tipranks.com/analysts/peter-galbo">here</a>.)</p> <p>They are:&nbsp;</p> <p>1. Recent third-party data points suggest U.S. sales are seeing a re-acceleration as more states open up. Most notably, Nielsen data for the week ended May 16 shows a 2.3% year-over-year ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16180646/4-reasons-why-this-monster-beverage-analyst-raised-their-price-target alt=4 Reasons Why This Monster Beverage Analyst Raised Their Price Target>Full story available on Benzinga.com</a></p> Analyst Color BofA Securities Coronavirus energy drinks MNST Peter Galbo Price Target Reiteration Analyst Ratings MNST Analyst Color Price Target Reiteration Analyst Ratings Benzinga Thu, 04 Jun 2020 17:46:47 +0000 Jayson Derrick 16180646 at https://www.benzinga.com What's Behind Chipotle Mexican Grill's Share Price Jump? https://www.benzinga.com/analyst-ratings/price-target/20/06/16175210/whats-behind-chipotle-mexican-grills-share-price-jump <p><strong>Chipotle Mexican Grill, Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cmg#NYSE">CMG</a>) shares are up nearly 4% so far this week, trading north of $1,000 per share.</p> <p>This comes just two months after the stock fell below $500.</p> <p>On Monday, Wedbush analyst <a href="https://www.tipranks.com/analysts/nick-setyan">Nick Setyan</a> maintained an Outperform on Chipotle and raised the price target&nbsp;from $870 to $1,200.</p> <p>Wedbush revised its estimates for second-quarter same-store sales from a 20% decline to a 9% decline.&nbsp;</p> <p>Chipotle reported substantial growth in its digital order volume during the start of the COVID-19 outbreak, with same-store ...</p><p><a href=https://www.benzinga.com/analyst-ratings/price-target/20/06/16175210/whats-behind-chipotle-mexican-grills-share-price-jump alt=What&#039;s Behind Chipotle Mexican Grill&#039;s Share Price Jump?>Full story available on Benzinga.com</a></p> CMG GRUB UBER Price Target Reiteration Restaurants Analyst Ratings Trading Ideas General CMG US1696561059 GRUB UBER Price Target Reiteration Restaurants Analyst Ratings Trading Ideas General Benzinga Thu, 04 Jun 2020 15:18:33 +0000 Drew Levine 16175210 at https://www.benzinga.com Zoom Analysts On Work-From-Home Boost, Churn Concerns After 'Historic' Q1 Print https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16170172/zoom-analysts-on-work-from-home-boost-churn-concerns-after-historic-q1-print <p><strong>Zoom Video Communications Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zm#NASDAQ">ZM</a>) <a href="https://www.benzinga.com/news/earnings/20/06/16164467/zoom-video-continues-huge-run-after-beat-and-qaise-q1-user-base-swells-amid-pandemic"> reported </a> a big first-quarter beat Tuesday, but the stock reaction has been muted as investors express uneasiness over a sky-high valuation.&nbsp;&nbsp;</p> <h3>The Zoom Analysts</h3> <p>KeyBanc Capital Markets analyst <a href="https://www.tipranks.com/analysts/alex-kurtz"> Alex Kurtz </a> maintained a Sector Weight rating on Zoom shares.</p> <p>Needham analyst <a href="https://www.tipranks.com/analysts/richard-valera"> Richard Valera </a> maintained a Buy rating and&nbsp;upped the price target from $140 to $230.</p> <p>Oppenheimer analyst <a href="https://www.tipranks.com/analysts/ittai-kidron"> Ittai Kidron </a> maintained a Perform rating.</p> <p>Cantor Fitzgerald analyst <a href="https://www.tipranks.com/analysts/drew-kootman"> Drew Kootman </a> maintained an Overweight rating and lifted the price target from $150 to $261.</p> <p>Stifel analyst <a href="https://www.tipranks.com/analysts/tom-roderick"> Tom Roderick </a> maintained a Hold rating and&nbsp;increased the price target from $105 to $180.</p> <h3>Focus On Zoom&#39;s Churn, KeyBanc Says</h3> <p>Zoom Video&#39;s first quarter is a historic one given the 169% year-over-year revenue growth and 346% billings growth, KeyBanc analyst Kurtz said. The analyst said the revenue contribution of sub-10-person users increased from 20% in the previous quarter to 30%, indicating smaller user cases.</p> <p>Investors are likely to focus on how churn plays out in the second half of the year as one-time users leave the platform, according to KeyBanc.&nbsp;</p> <h3>Zoom Has Multiyear Growth Runway, Needham Says</h3> <p>Zoom Video smashed its first-quarter print and guidance, a performance not seen in 20-pls&nbsp;years of Needham&#39;s tech coverage, analyst Valera said.</p> <p>The analyst sees two conflicting dynamics driving the company&#39;s results in the near-term:&nbsp;increased churn relative to historical levels&nbsp;and increased opportunity from both a lasting secular shift toward remote work and ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16170172/zoom-analysts-on-work-from-home-boost-churn-concerns-after-historic-q1-print alt=Zoom Analysts On Work-From-Home Boost, Churn Concerns After &#039;Historic&#039; Q1 Print>Full story available on Benzinga.com</a></p> Alex Kurtz Analyst Color Cantor Fitzgerald CSCO Drew Kootman Earnings Gene Munster Ittai Kidron KeyBanc Capital Markets Loup Ventures MSFT Nedham News Richard Valera Stifel Tom Roderick ZM Price Target Reiteration Analyst Ratings Tech Trading Ideas CSCO US17275R1023 MSFT US5949181045 ZM News Analyst Color Earnings Price Target Reiteration Analyst Ratings Tech Trading Ideas Benzinga Wed, 03 Jun 2020 19:34:02 +0000 Shanthi Rexaline 16170172 at https://www.benzinga.com What Crowdstrike Analysts Are Saying After Q1 Beat: 'A Unique Investment Vehicle' https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16169584/what-crowdstrike-analysts-are-saying-after-q1-beat-a-unique-investment-vehicle <p>Cybersecurity company <strong>Crowdstrike Holdings Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crwd#NASDAQ">CRWD</a>) reported <a href="https://www.benzinga.com/pressreleases/20/06/b16163716/crowdstrike-reports-fiscal-first-quarter-2021-financial-results">first-quarter</a> results Tuesday highlighted by an 89% year-over-year subscription growth, $686 million in annual recurring revenue and improving free cash flow from negative $16.1 million last year to positive $87 million.</p> <p>Here&#39;s how some of the Street&#39;s top analysts reacted to the report.</p> <h3>The Crowdstrike Analysts</h3> <p>Needham analyst <a href="https://www.tipranks.com/analysts/alex-henderson">Alex Henderson</a> maintains at Buy, price target lifted from $105 to $120.</p> <p>Oppenheimer analyst <a href="https://www.tipranks.com/analysts/shaul-eyal">Shaul Eyal</a> maintains at Outperform, price target lifted from $85 to $110.</p> <p>Credit Suisse analyst <a href="https://www.tipranks.com/analysts/brad-zelnick">Brad Zelnick</a> maintains at Neutral, price target lifted from $65 to $80.</p> <p>Tigress Financial Partners CIO <a href="https://www.tipranks.com/analysts/ivan-feinseth">Ivan Feinseth</a>&nbsp;commented on Crowdstrike in his daily newsletter.&nbsp;</p> <h3>Needham Sees Across-The-Board Strength In Crowdstrike&nbsp;</h3> <p>Crowdstrike&#39;s go-to-market and highly scalable installation capabilities &quot;shined&quot; in the current &quot;COVID constrained environment,&quot; Henderson said&nbsp;in a Wednesday note.</p> <p>This is supported by strength seen nearly across the board in the quarter, the analyst said:</p> <ul> <li>105% growth in new customers.</li> <li>Revenue growth of 85% versus 73% on the high end of management&#39;s guidance.</li> <li>Gross margins up 500 basis points to 77%.</li> <li>Operating margins improved 2,300 basis points year-over-year.</li> <li>ARR came in $40 million better than ...</li></ul><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16169584/what-crowdstrike-analysts-are-saying-after-q1-beat-a-unique-investment-vehicle alt=What Crowdstrike Analysts Are Saying After Q1 Beat: &#039;A Unique Investment Vehicle&#039;>Full story available on Benzinga.com</a></p> AKAM Alex Henderson Analyst Color Brad Zelnick cloud Credit Suisse CRWD Cybersecurity Earnings Ivan Feinseth Needham News Oppenheimer Shaul Eyal Tigress Financial Partners Guidance Price Target Reiteration Top Stories Analyst Ratings AKAM US00971T1016 CRWD News Analyst Color Earnings Guidance Price Target Reiteration Top Stories Analyst Ratings Benzinga Wed, 03 Jun 2020 16:40:15 +0000 Jayson Derrick 16169584 at https://www.benzinga.com Morgan Stanley Bullish On Rising App Store Revenue, Raises Apple Price Target https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16168978/morgan-stanley-bullish-on-rising-app-store-revenue-raises-apple-price-target <p>Data from Sensor Tower points to <strong>Apple Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aapl#NASDAQ">AAPL</a>) growing its <a href="http://benzinga.com/topic/app-store">App Store</a> net revenue by 39% year-over-year in May, and this trend bodes well for the stock, according to Morgan Stanley.</p> <h3>The Apple Analyst</h3> <p><a href="https://www.tipranks.com/analysts/kathryn-huberty">Katy Huberty</a> maintained&nbsp;an Overweight rating on Apple&nbsp;and lifted the price target from $326 to $340.</p> <h3>The Apple Thesis</h3> <p>Apple&#39;s App Store performance in May could prove to be the strongest year-over-year growth seen since April 2017, Huberty said in a Wednesday note. (See her track record <a href="http://www.tipranks.com/analysts/kathryn-huberty">here</a>.)</p> <p>Since the start of the second calendar quarter, App Store net revenue is tracking higher by 35% year-over-year, and this is &quot;meaningfully&quot; higher than expectations for ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16168978/morgan-stanley-bullish-on-rising-app-store-revenue-raises-apple-price-target alt=Morgan Stanley Bullish On Rising App Store Revenue, Raises Apple Price Target>Full story available on Benzinga.com</a></p> AAPL Analyst Color App Store Apps Katy Huberty Morgan Stanley Sensor Tower Price Target Reiteration Analyst Ratings Tech AAPL US0378331005 Analyst Color Price Target Reiteration Analyst Ratings Tech Benzinga Wed, 03 Jun 2020 15:00:13 +0000 Jayson Derrick 16168978 at https://www.benzinga.com Euronet Worldwide: DA Davidson's Payments Alternative To Western Union, MoneyGram https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16160438/euronet-worldwide-da-davidsons-payments-alternative-to-western-union-moneygram <p><strong>The Western Union Company</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wu#NYSE">WU</a>) is <a href="https://www.benzinga.com/m-a/20/06/16156730/moneygram-shares-jump-50-as-western-union-reportedly-looks-for-acquisition">reportedly looking</a> to acquire <strong>Moneygram International Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mgi#NASDAQ">MGI</a>) in a merger that looks unappealing for investors, according to D.A. Davidson.&nbsp;</p> <h3>The Euronet Worldwide Analyst</h3> <p><a href="https://www.tipranks.com/analysts/peter-heckmann">Peter Heckmann</a> maintained&nbsp;a Buy rating on rival <strong>Euronet Worldwide, Inc.</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/eeft#NASDAQ">EEFT</a>) with a $150 price target.&nbsp;</p> <h3>The Euronet Worldwide Thesis</h3> <p>Western Union is the largest branded money transfer company, with an approximate 12% market share, while Moneygram is a top-five player with an approximate 5% share, Heckmann said&nbsp;in a Tuesday note. (See his track record <a href="http://www.tipranks.com/analysts/peter-heckmann">here</a>.)</p> <p>A combination of the two won&#39;t result in a stronger entity; will&nbsp;face regulatory scrutiny; and will take time to ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16160438/euronet-worldwide-da-davidsons-payments-alternative-to-western-union-moneygram alt=Euronet Worldwide: DA Davidson&#039;s Payments Alternative To Western Union, MoneyGram>Full story available on Benzinga.com</a></p> Analyst Color DA Davidson EEFT MGI payments Peter Heckmann WU Price Target Reiteration Analyst Ratings Movers Trading Ideas EEFT US2987361092 MGI US60935Y2081 WU US9598021098 Analyst Color Price Target Reiteration Analyst Ratings Movers Trading Ideas Benzinga Tue, 02 Jun 2020 19:10:17 +0000 Jayson Derrick 16160438 at https://www.benzinga.com Why BofA Recommends Buying GPU Plays AMD and Nvidia https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16159710/why-bofa-recommends-buying-gpu-plays-amd-and-nvidia <p><strong>Advanced Micro Devices, Inc. </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amd#NASDAQ">AMD</a>) and <strong>NVIDIA Corporation </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) are among the best performing tech stocks in the year-to-date period. Despite the runup, an analyst at BofA Securities recommends buying into these GPU plays.</p> <h3><strong>The Analyst</strong></h3> <p><a href="http://www.tipranks.com/analysts/vivek-arya">Vivek Arya</a> has Buy ratings on both Nvidia and AMD shares, with&nbsp;price targets of $420 and $65, respectively.</p> <h3><strong>The Thesis</strong></h3> <p>Arya said the $8 billion market in 2019 comprised of PC gaming, which accounted for 70% of the total market and declined 14% year-over-year, traditional PCs, accounting for roughly 12% of the market and showing 3% year-over-year growth, and gaming consoles, which made up the remaining 18% of the market and declined ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16159710/why-bofa-recommends-buying-gpu-plays-amd-and-nvidia alt=Why BofA Recommends Buying GPU Plays AMD and Nvidia>Full story available on Benzinga.com</a></p> AMD Analyst Color BofA Securities NVDA Vivek Arya Reiteration Analyst Ratings Tech Trading Ideas NVDA US67066G1040 AMD US0079031078 Analyst Color Reiteration Analyst Ratings Tech Trading Ideas Benzinga Tue, 02 Jun 2020 17:20:06 +0000 Shanthi Rexaline 16159710 at https://www.benzinga.com Inovio Analyst Watches Coronavirus Play 'From The Sidelines' https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16159984/inovio-analyst-watches-coronavirus-play-from-the-sidelines <p>Coronavirus vaccine play <strong>Inovio Pharmaceuticals Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ino#NASDAQ">INO</a>) is not an outright buy at this point in time, according to an analyst at Piper Sandler.</p> <h3>The Inovio Analyst</h3> <p><a href="http://www.tipranks.com/analysts/christopher-raymond">Christopher Raymond</a> maintained a Neutral rating on <a href="https://www.benzinga.com/analyst-ratings/analyst-color/20/04/15908539/inovio-analysts-project-about-24-upside-potential-amid-optimism-on-coronavirus-dna-"> Inovio shares </a>with an&nbsp;$8 price target.&nbsp;</p> <h3>The Inovio Thesis</h3> <p>The 12-month overall survival data Inovio presented for its DNA cancer vaccine INO-5401 in glioblastoma multiforme &mdash;&nbsp;a deadly form of brain cancer &mdash;&nbsp;at the ASCO made the benefit less clear, Raymond said in a Monday note. (See his track record <a href="http://www.tipranks.com/analysts/christopher-raymond">here</a>.)&nbsp;</p> <p>The vaccine is being studied in a Phase 2 single-arm study in newly diagnosed GBM patients following gross total resection and in combo ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16159984/inovio-analyst-watches-coronavirus-play-from-the-sidelines alt=Inovio Analyst Watches Coronavirus Play &#039;From The Sidelines&#039;>Full story available on Benzinga.com</a></p> Analyst Color Biotech Christopher Raymond Coronavirus Covid-19 INO Piper Sandler REGN Price Target Reiteration Analyst Ratings General INO US45773H1023 REGN US75886F1075 Analyst Color Biotech Price Target Reiteration Analyst Ratings General Benzinga Tue, 02 Jun 2020 15:31:58 +0000 Shanthi Rexaline 16159984 at https://www.benzinga.com SpaceX Falcon 9 Launch A 'Major Shot In The Arm' For Tesla Brand, Analyst Says https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16153092/spacex-falcon-9-launch-a-major-shot-in-the-arm-for-tesla-brand-analyst-says <p><strong>Tesla Inc</strong> (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsla#NASDAQ">TSLA</a>) shares traded higher by 5.8% on Monday following a <a href="https://www.benzinga.com/news/20/06/16147025/nasa-astronauts-launched-by-spacex-reach-international-space-station-celebrate-historic-moment">successful launch by&nbsp;CEO Elon Musk&rsquo;s other company</a>, <strong>SpaceX</strong>.</p> <p>While Tesla and SpaceX have only loose financial ties, one analyst says&nbsp;SpaceX is contributing value to Tesla&rsquo;s brand.</p> <h3><strong>The Tesla Analyst</strong></h3> <p>Wedbush analyst <a href="https://www.tipranks.com/analysts/daniel-ives">Daniel Ives </a>reiterated a Neutral rating and $800 price target for Tesla.</p> <h3><strong>The Tesla Thesis</strong></h3> <p>On Saturday, SpaceX became the first private company to successfully launch NASA astronauts into space when the company&rsquo;s Falcon 9 rocket took off from Kennedy Space Center in Florida.</p> <p>&ldquo;While SpaceX and Tesla are separate companies despite some R&amp;D cross pollination in some key areas, from a consumer perspective the Musk DNA remains the linchpin to both of these next generation technology stalwarts and we would characterize the historic success of SpaceX as another major shot in the arm to the Tesla brand,&rdquo; Ives wrote in a Monday note.</p> <p>Ives said Tesla appears to be on track ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16153092/spacex-falcon-9-launch-a-major-shot-in-the-arm-for-tesla-brand-analyst-says alt=SpaceX Falcon 9 Launch A &#039;Major Shot In The Arm&#039; For Tesla Brand, Analyst Says>Full story available on Benzinga.com</a></p> Analyst Color Daniel Ives Elon Musk Mark Spiegel NASA SpaceX Stanphyl Capital TSLA Wedbush Price Target Reiteration Analyst Ratings TSLA US88160R1014 Analyst Color Price Target Reiteration Analyst Ratings Benzinga Mon, 01 Jun 2020 20:35:23 +0000 Wayne Duggan 16153092 at https://www.benzinga.com Pfizer Analyst Takes Stock Of Negative Breast Cancer Data, Pharma Giant's 2025 Goals https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16151451/pfizer-analyst-takes-stock-of-negative-breast-cancer-data-pharma-giants-2025-goals <p><strong>Pfizer Inc. </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>) shares were&nbsp;declining steeply Monday after the company <a href="https://www.benzinga.com/news/20/05/16143680/pfizer-falls-on-disappointing-breast-cancer-pallas-study"> said </a>a&nbsp;Phase 3 study dubbed PALLAS that evaluated its Ibrance with standard adjuvant endocrine therapy in&nbsp;HR+, HER-, early stage breast cancer study is unlikely to hit the primary goal, citing efficacy and futility analysis done by an Independent Data Monitoring Committee.</p> <h3>The Pfizer Analyst</h3> <p>Cantor Fitzgerald analyst <a href="http://www.tipranks.com/analysts/louise-chen">Louise Chen</a> maintained an Overweight rating on <a href="http://www.benzinga.com/news/earnings/20/06/16146999/5-stocks-to-watch-for-june-1-2020">Pfizer shares</a> with a&nbsp;$53 price target.&nbsp;</p> <h3>The Pfizer Thesis</h3> <p>The adjuvant opportunity for the breast cancer drug Ibrance is being viewed by investors as a key growth driver for Pfizer,&nbsp;Chen said in a Friday note. (See her track record <a href="http://www.tipranks.com/analysts/louise-chen">here</a>.)</p> <p>The analyst said she expects the consensus sales&nbsp;estimate for Ibrance to come down to reflect a lower opportunity.</p> <p>Pfizer had earlier ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16151451/pfizer-analyst-takes-stock-of-negative-breast-cancer-data-pharma-giants-2025-goals alt=Pfizer Analyst Takes Stock Of Negative Breast Cancer Data, Pharma Giant&#039;s 2025 Goals>Full story available on Benzinga.com</a></p> Analyst Color Biotech Cantor Fitzgerald ibrance Louise Chen PFE Price Target Reiteration Analyst Ratings General PFE US7170811035 Analyst Color Biotech Price Target Reiteration Analyst Ratings General Benzinga Mon, 01 Jun 2020 18:25:39 +0000 Shanthi Rexaline 16151451 at https://www.benzinga.com Zoom Analyst Sees 'Minimal' Near-Term Upside Ahead Of Q1 Report https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16150596/zoom-analyst-sees-minimal-near-term-upside-ahead-of-q1-report <p><strong>Zoom Video Communications Inc </strong>(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zm#NASDAQ">ZM</a>) has zoomed past levels that could render the valuation attractive, leaving scope for &quot;minimal&quot;&nbsp;near-term upside, an analyst at Rosenblatt Securities said ahead of the company&#39;s Tuesday first-quarter report.&nbsp;</p> <h3>The Zoom Analyst</h3> <p><a href="http://www.tipranks.com/analysts/ryan-koontz">Ryan Koontz</a> maintained a Neutral rating and&nbsp;<a href="https://www.benzinga.com/analyst-ratings/price-target/20/06/16148982/10-biggest-price-target-changes-for-monday">upped </a> the price target from $95 to $150.</p> <h3>The Zoom Thesis</h3> <p>Zoom is likely to report very strong revenues&nbsp;but in-line earnings results due to higher opex and &quot;freemium&quot;&nbsp;products costs, Koontz said in a Friday note. (See his track record <a href="http://www.tipranks.com/analysts/ryan-koontz">here</a>.)</p> <p>Rosenblatt expects the company to raise its second-quarter and second-half revenue guidance, the analyst said.&nbsp;</p> <p>The coronavirus pandemic has transformed Zoom&#39;s &quot;laser-focused business ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16150596/zoom-analyst-sees-minimal-near-term-upside-ahead-of-q1-report alt=Zoom Analyst Sees &#039;Minimal&#039; Near-Term Upside Ahead Of Q1 Report>Full story available on Benzinga.com</a></p> Analyst Color Earnings News Rosenblatt Securities Ryan Koontz ZM Guidance Price Target Previews Reiteration Analyst Ratings Movers Tech Trading Ideas ZM News Analyst Color Earnings Guidance Price Target Previews Reiteration Analyst Ratings Movers Tech Trading Ideas Benzinga Mon, 01 Jun 2020 16:52:44 +0000 Shanthi Rexaline 16150596 at https://www.benzinga.com Aphria, Aurora Analyst Says Buy The Dip To Take Advantage Of Cannabis Stock Sell-Off https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16150569/aphria-aurora-analyst-says-buy-the-dip-to-take-advantage-of-cannabis-stock-sell-off <p>Canadian cannabis stocks tumbled Friday after <strong>Canopy Growth Corp</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>) reported a significant miss for its March quarter sales and withdrew its outlook for reaching positive EBITDA. Canopy also expressed concern over the company&rsquo;s June quarter prospects.</p> <p>The problems witnessed by Canopy Growth in the March quarter seem to be company-specific, and the broader sell-off among the group makes <strong>Aphria Inc </strong>(NYSE: <a class="ticker" href="https://www.benzinga.com/stock/apha#NYSE">APHA</a>) and <strong>Aurora Cannabis Inc</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/acb#NYSE">ACB</a>) even more attractive, according to Cantor Fitzgerald.</p> <h3>The Aphria, Aurora Analyst</h3> <p><a href="https://www.tipranks.com/analysts/pablo-zuanic">Pablo Zuanic</a> maintained Overweight ratings on both Aphria and Aurora Cannabis, with price targets of CA$9.55 ($6.97) ...</p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/06/16150569/aphria-aurora-analyst-says-buy-the-dip-to-take-advantage-of-cannabis-stock-sell-off alt=Aphria, Aurora Analyst Says Buy The Dip To Take Advantage Of Cannabis Stock Sell-Off>Full story available on Benzinga.com</a></p> ACB Analyst Color APHA Cannabis Cannabis 2.0 Cantor Fitzgerald CGC Earnings News Pablo Zuanic Pot Stocks Guidance Price Target Reiteration Markets Analyst Ratings Trading Ideas CGC ACB APHA News Analyst Color Earnings Cannabis Guidance Price Target Reiteration Markets Analyst Ratings Trading Ideas Benzinga Mon, 01 Jun 2020 16:21:11 +0000 Priya Nigam 16150569 at https://www.benzinga.com What 2 Experts Are Saying About Canopy Growth After The Q4 Print https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16141383/what-2-experts-are-saying-about-canopy-growth-after-the-q4-print <p><strong>Canopy Growth Corporation</strong> (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cgc#NYSE">CGC</a>) reported mixed fourth-quarter earnings results Thursday. The company reported a year-over-year decrease in earnings per share&nbsp;and an increase in net revenue.</p> <h3><strong>The&nbsp;Experts</strong></h3> <p>Eric Choe, founder of <a href="https://twitter.com/StockDweebs">StockDweebs</a>, says Canopy Growth is well-positioned to rally from the production, distribution&nbsp;and sale of its cannabis products despite the recent downfall.</p> <p>&ldquo;It relies primarily on retail traffic and the sale of medicinal and recreational cannabis products - this could boost overall sales and top-line figures once stores start opening post-COVID,&rdquo; Choe said.</p> <p><em><strong>Canopy Growth&nbsp;is slated to speak ...</strong></em></p><p><a href=https://www.benzinga.com/analyst-ratings/analyst-color/20/05/16141383/what-2-experts-are-saying-about-canopy-growth-after-the-q4-print alt=What 2 Experts Are Saying About Canopy Growth After The Q4 Print>Full story available on Benzinga.com</a></p> Analyst Color Cannabis Cantor Fitzgerald CGC Earnings Eric Choe News Pablo Zuanic StockDweebs Price Target Reiteration Markets Analyst Ratings Movers Trading Ideas CGC News Analyst Color Earnings Cannabis Price Target Reiteration Markets Analyst Ratings Movers Trading Ideas Benzinga Fri, 29 May 2020 19:10:09 +0000 Randy Elias 16141383 at https://www.benzinga.com